Closing Thoughts on Enfortumab Vedotin Plus Pembrolizumab in Patients With Advanced Urothelial Carcinoma


Rohit Gosain, MD, and Rahul Gosain, MD, provide a summary of the key data discussed during their conversation with Jonathan E. Rosenberg, MD, on the phase 2 EV-103 trial in metastatic or locally advanced urothelial carcinoma.

Related Videos
Related Content